72 related articles for article (PubMed ID: 18318756)
1. Effect of deferasirox (ICL670) on arterial function in patients with beta-thalassaemia major.
Cheung YF; Chan GC; Ha SY
Br J Haematol; 2008 May; 141(5):728-33. PubMed ID: 18318756
[TBL] [Abstract][Full Text] [Related]
2. Arterial stiffness and endothelial function in patients with beta-thalassemia major.
Cheung YF; Chan GC; Ha SY
Circulation; 2002 Nov; 106(20):2561-6. PubMed ID: 12427652
[TBL] [Abstract][Full Text] [Related]
3. Oxidised low-density lipoprotein and arterial function in beta-thalassemia major.
Stakos DA; Tavridou A; Margaritis D; Tziakas DN; Kotsianidis I; Chalikias GK; Tsatalas K; Bourikas G; Manolopoulos VG; Boudoulas H
Eur J Haematol; 2009 Jun; 82(6):477-83. PubMed ID: 19220416
[TBL] [Abstract][Full Text] [Related]
4. Deferasirox effect on renal haemodynamic parameters in patients with transfusion-dependent β thalassaemia.
Piga A; Fracchia S; Lai ME; Cappellini MD; Hirschberg R; Habr D; Wegener A; Bouillaud E; Forni GL
Br J Haematol; 2015 Mar; 168(6):882-90. PubMed ID: 25402221
[TBL] [Abstract][Full Text] [Related]
5. Improved efficacy and tolerability of oral deferasirox by twice-daily dosing for patients with transfusion-dependent β-thalassemia.
Chang HH; Lu MY; Liao YM; Lin PC; Yang YL; Lin DT; Chiou SS; Jou ST; Lin KH; Chang TT
Pediatr Blood Cancer; 2011 Mar; 56(3):420-4. PubMed ID: 21072825
[TBL] [Abstract][Full Text] [Related]
6. Advanced glycation endproduct crosslink breaker (alagebrium) improves endothelial function in patients with isolated systolic hypertension.
Zieman SJ; Melenovsky V; Clattenburg L; Corretti MC; Capriotti A; Gerstenblith G; Kass DA
J Hypertens; 2007 Mar; 25(3):577-83. PubMed ID: 17278974
[TBL] [Abstract][Full Text] [Related]
7. Endothelial function and arterial stiffness in normotensive normoglycemic first-degree relatives of diabetic patients are independent of the metabolic syndrome.
Scuteri A; Tesauro M; Rizza S; Iantorno M; Federici M; Lauro D; Campia U; Turriziani M; Fusco A; Cocciolillo G; Lauro R
Nutr Metab Cardiovasc Dis; 2008 Jun; 18(5):349-56. PubMed ID: 17935958
[TBL] [Abstract][Full Text] [Related]
8. Deferasirox administration for the treatment of non-transfusional iron overload in patients with thalassaemia intermedia.
Ladis V; Berdousi H; Gotsis E; Kattamis A
Br J Haematol; 2010 Dec; 151(5):504-8. PubMed ID: 20950401
[TBL] [Abstract][Full Text] [Related]
9. Endothelial function and arterial stiffness in sickle-thalassemia patients.
Aessopos A; Farmakis D; Tsironi M; Diamanti-Kandarakis E; Matzourani M; Fragodimiri C; Hatziliami A; Karagiorga M
Atherosclerosis; 2007 Apr; 191(2):427-32. PubMed ID: 16712855
[TBL] [Abstract][Full Text] [Related]
10. Increase in carotid artery intima-media thickness and arterial stiffness but improvement in several markers of endothelial function after initiation of antiretroviral therapy.
van Vonderen MG; Hassink EA; van Agtmael MA; Stehouwer CD; Danner SA; Reiss P; Smulders Y
J Infect Dis; 2009 Apr; 199(8):1186-94. PubMed ID: 19275490
[TBL] [Abstract][Full Text] [Related]
11. Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major.
Galanello R; Piga A; Forni GL; Bertrand Y; Foschini ML; Bordone E; Leoni G; Lavagetto A; Zappu A; Longo F; Maseruka H; Hewson N; Sechaud R; Belleli R; Alberti D
Haematologica; 2006 Oct; 91(10):1343-51. PubMed ID: 17018383
[TBL] [Abstract][Full Text] [Related]
12. The effect of acute fish-oil supplementation on endothelial function and arterial stiffness following a high-fat meal.
Fahs CA; Yan H; Ranadive S; Rossow LM; Agiovlasitis S; Wilund KR; Fernhall B
Appl Physiol Nutr Metab; 2010 Jun; 35(3):294-302. PubMed ID: 20555373
[TBL] [Abstract][Full Text] [Related]
13. Immunological evaluation of β-thalassemia major patients receiving oral iron chelator deferasirox.
Aleem A; Shakoor Z; Alsaleh K; Algahtani F; Iqbal Z; Al-Momen A
J Coll Physicians Surg Pak; 2014 Jul; 24(7):467-71. PubMed ID: 25052967
[TBL] [Abstract][Full Text] [Related]
14. Improvement in liver pathology of patients with β-thalassemia treated with deferasirox for at least 3 years.
Deugnier Y; Turlin B; Ropert M; Cappellini MD; Porter JB; Giannone V; Zhang Y; Griffel L; Brissot P
Gastroenterology; 2011 Oct; 141(4):1202-11, 1211.e1-3. PubMed ID: 21741344
[TBL] [Abstract][Full Text] [Related]
15. Large and small artery endothelial function in patients with essential hypertension--effect of ACE inhibition and beta-blockade.
Buus NH; Jørgensen CG; Mulvany MJ; Sørensen KE
Blood Press; 2007; 16(2):106-13. PubMed ID: 17612909
[TBL] [Abstract][Full Text] [Related]
16. Coenzyme Q10 levels in β-thalassemia and its association with ferritin levels and chelation therapy.
Karakukcu C; Karakukcu M; Unal E; Patiroglu T; Ozdemir MA; Torun YA; Tang PH
Hemoglobin; 2012; 36(3):219-29. PubMed ID: 22483337
[TBL] [Abstract][Full Text] [Related]
17. Kidney transplantation improves arterial function measured by pulse wave analysis and endothelium-independent dilatation in uraemic patients despite deterioration of glucose metabolism.
Hornum M; Clausen P; Idorn T; Hansen JM; Mathiesen ER; Feldt-Rasmussen B
Nephrol Dial Transplant; 2011 Jul; 26(7):2370-7. PubMed ID: 21097648
[TBL] [Abstract][Full Text] [Related]
18. The impact of two different doses of chelating therapy (deferasirox) on echocardiographic tissue Doppler indices in patients with thalassemia major.
Garadah TS; Mahdi N; Kassab S; Abu-Taleb A; Shoroqi I; Alawadi AH
Eur J Haematol; 2011 Sep; 87(3):267-73. PubMed ID: 21554401
[TBL] [Abstract][Full Text] [Related]
19. Inflammation and oxidant-stress in beta-thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trial.
Walter PB; Macklin EA; Porter J; Evans P; Kwiatkowski JL; Neufeld EJ; Coates T; Giardina PJ; Vichinsky E; Olivieri N; Alberti D; Holland J; Harmatz P;
Haematologica; 2008 Jun; 93(6):817-25. PubMed ID: 18469351
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of deferasirox in North Indian β-thalassemia major patients: a preliminary report.
Panigrahi I; Vaidya PC; Bansal D; Marwaha RK
J Pediatr Hematol Oncol; 2012 Jan; 34(1):51-3. PubMed ID: 22215098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
